JP6936236B2 - 治療化合物、組成物及びその方法の使用 - Google Patents

治療化合物、組成物及びその方法の使用 Download PDF

Info

Publication number
JP6936236B2
JP6936236B2 JP2018539129A JP2018539129A JP6936236B2 JP 6936236 B2 JP6936236 B2 JP 6936236B2 JP 2018539129 A JP2018539129 A JP 2018539129A JP 2018539129 A JP2018539129 A JP 2018539129A JP 6936236 B2 JP6936236 B2 JP 6936236B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
group
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018539129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505529A (ja
JP2019505529A5 (enExample
Inventor
ギボンズ，ポール
ケラー，テリー
ザック，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2019505529A publication Critical patent/JP2019505529A/ja
Publication of JP2019505529A5 publication Critical patent/JP2019505529A5/ja
Application granted granted Critical
Publication of JP6936236B2 publication Critical patent/JP6936236B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
JP2018539129A 2016-02-18 2017-02-17 治療化合物、組成物及びその方法の使用 Expired - Fee Related JP6936236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297061P 2016-02-18 2016-02-18
US62/297,061 2016-02-18
PCT/EP2017/053576 WO2017140825A1 (en) 2016-02-18 2017-02-17 Therapeutic compounds, compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019505529A JP2019505529A (ja) 2019-02-28
JP2019505529A5 JP2019505529A5 (enExample) 2020-03-26
JP6936236B2 true JP6936236B2 (ja) 2021-09-15

Family

ID=58054137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539129A Expired - Fee Related JP6936236B2 (ja) 2016-02-18 2017-02-17 治療化合物、組成物及びその方法の使用

Country Status (5)

Country Link
US (2) US20180354959A1 (enExample)
EP (1) EP3416967B1 (enExample)
JP (1) JP6936236B2 (enExample)
CN (1) CN108473501B (enExample)
WO (1) WO2017140825A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102662215B1 (ko) 2014-11-06 2024-05-02 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
JP7034935B2 (ja) 2016-04-06 2022-03-14 リソソーマル・セラピューティクス・インコーポレイテッド ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
CN110678467B (zh) * 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
MA56518A (fr) * 2019-06-18 2022-04-27 Hoffmann La Roche Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2014039595A1 (en) * 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN105899505B (zh) * 2013-11-08 2018-08-28 武田药品工业株式会社 用于治疗自身免疫病症的吡唑
US9346815B2 (en) * 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

Also Published As

Publication number Publication date
US11795170B2 (en) 2023-10-24
CN108473501B (zh) 2021-07-16
EP3416967A1 (en) 2018-12-26
EP3416967B1 (en) 2022-02-09
WO2017140825A1 (en) 2017-08-24
JP2019505529A (ja) 2019-02-28
HK1259372A1 (zh) 2019-11-29
CN108473501A (zh) 2018-08-31
US20180354959A1 (en) 2018-12-13
US20210009599A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP6936236B2 (ja) 治療化合物、組成物及びその方法の使用
JP7041198B2 (ja) Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物
JP6914933B2 (ja) ヤヌスキナーゼ、並びにその組成物及びその使用
JP6900491B2 (ja) ピラゾロピリミジン化合物及びその使用方法
JP7059268B2 (ja) ＩＲＡＫ４モデュレーターとしてのピラゾロ［１，５ａ］ピリミジン誘導体
JP2020524692A (ja) Ｉｒａｋ４調節因子としてのベンゾフラン
US11649241B2 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
US20230242530A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
JP7339263B2 (ja) Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
US10189836B2 (en) Therapeutic compounds, compositions and methods of use thereof
HK1259372B (zh) 治疗化合物、其组合物及使用方法
HK1258765B (en) Therapeutic compounds, compositions and methods of use thereof
HK40017827A (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
HK40009645B (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40009645A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210826

R150 Certificate of patent or registration of utility model

Ref document number: 6936236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees